BIOCRYST PHARMACEUTICALS INC (BCRX): Results of Operations and Financial Condition
BIOCRYST PHARMACEUTICALS INC (BCRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFiling EXHIBIT 99.1 BioCryst Reports Second Quarter 2026 Financial Results — Total net revenue of $218.3 million and ORLADEYO ® net revenue of $158.2 million — — Operating profit of $98.5 million and Non-GAAP operating profit of $113.2 mil
How this was made
The 30-second read
Why it matters
Traders can update models using the raised 2026 total revenue range, track pediatric ORLADEYO oral pellet launch ramp, and monitor ALPHA-ORBIT enrollment completion toward Q3 2027 topline.
Market read
The filing combines a guidance raise with concrete commercialization and clinical execution milestones, creating actionable updates for revenue and probability-weighted pipeline expectations.
What to watch
ORLADEYO oral pellet shipments are early (started week of Aug. 3) and prescription approvals are still ramping; execution risk in pediatric uptake could temper follow-through.
Background
This is BioCryst’s SEC Form 8-K with Q2 2026 financial results and business updates, including ORLADEYO commercialization progress and pipeline trial milestones.
Ticker impact
BioCryst reported Q2 2026 results and raised full-year 2026 total revenue guidance to $690M-$715M while maintaining ORLADEYO revenue guidance.
Likely positive bias for the stock into the next earnings cycle, with upside sensitivity to ORLADEYO prescription growth and pediatric launch execution.
The filing includes multiple fresh, decision-relevant datapoints: Q2 revenue and operating profit, raised total revenue outlook, start of pediatric oral pellet shipments, and completion of pivotal enrollment with a stated Q3 2027 topline timeline.
Market effects
Reinforces investor appetite for rare-disease commercial launches and pipeline execution in plasma kallikrein inhibitor franchises.
Limited direct regional read-through beyond Europe licensing economics for navenibart.
Global revenue guidance update and Europe commercialization licensing can affect expectations for cross-region rare-disease revenue mix.
Counterpoint
Raised total revenue guidance may be partially offset by higher R&D spend and milestone/royalty timing, so near-term upside could be less than it appears on headline guidance.
Key entities
- issuerBioCryst Pharmaceuticals, Inc.
Nasdaq-listed company reporting Q2 2026 results, ORLADEYO pediatric launch progress, and updated 2026 revenue guidance.
- productORLADEYO
BioCryst’s hereditary angioedema therapy; oral pellet shipments to pediatric patients began Aug. 3, 2026.
- clinical_programnavenibart (ALPHA-ORBIT)
Investigational long-acting plasma kallikrein inhibitor; ALPHA-ORBIT enrollment completed, topline expected Q3 2027.
- partnerCareMed
New commercial pharmacy partner for ORLADEYO shipments, becoming sole specialty pharmacy source beginning Q3 2026.
- licensing_counterpartyNeopharmed Gentili (Irish affiliate)
Partner in a licensing agreement granting exclusive European commercialization rights for navenibart.
